Trials / Recruiting
RecruitingNCT07221357
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 990 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pumitamig | Specified dose on specified days |
| DRUG | FOLFOX | Specified dose on specified days |
| DRUG | FOLFIRI | Specified dose on specified days |
| DRUG | Bevacizumab | Specified dose on specified days |
| DRUG | CAPOX | Specified dose on specified days |
Timeline
- Start date
- 2025-12-31
- Primary completion
- 2030-02-02
- Completion
- 2034-03-11
- First posted
- 2025-10-27
- Last updated
- 2026-03-31
Locations
263 sites across 26 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Hungary, India, Italy, Japan, Netherlands, Poland, Romania, Singapore, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07221357. Inclusion in this directory is not an endorsement.